ATNM Actinium Pharmaceuticals, Inc.

1.53
+0  (1%)
Previous Close 1.51
Open 1.50
Price To book 4.67
Market Cap 85.38M
Shares 55,807,000
Volume 350,046
Short Ratio 2.53
Av. Daily Volume 901,368

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 initiated September 2016. Interim analysis due mid-2017.
Actimab-A
Acute Myeloid Leukemia (AML)
Phase 3 initiated June 2016. Data due 1H 2018.
Iomab-B
Hematopoietic Stem Cells Transplantation

Latest News

  1. Actinium Pharmaceuticals Announces Sponsorship of the Acute Leukemia Forum 2017
  2. Actinium Pharmaceuticals Appoints Pharmaceutical Industry Executive Ajit S. Shetty, Ph.D., to the Company’s Board of Directors
  3. Moleculin Leukemia Drug Gets Orphan Drug Status
  4. Actinium Gets Positive CHMP Opinion for AML Drug
  5. Actinium Pharmaceuticals (ATNM) Receives New Patents, Boosts its Portfolio
  6. Actinium Announces Receipt of Positive Scientific Advice from the European Medicines Agency for Iomab-B
  7. Actinium Pharmaceuticals to Sponsor 4th Annual Summit on Hematologic Malignancies
  8. Actinium Pharmaceuticals to Present at 29th Annual ROTH Conference
  9. Actinium Announces Expansion of Intellectual Property Portfolio with Notice of Allowance for U.S. Patent Related to Actimab-A, Actimab-M and the Company’s Technology Platform
  10. Actinium Pharmaceuticals Announces Active Presence at the BMT Tandem Meetings
  11. Actinium Pharmaceuticals Announces Hiring of Steven Price to Position of Vice President, Clinical and Commercial Strategy
  12. Actinium Pharmaceuticals to Attend the BMT Tandem Meetings, the Combined Annual Meetings of Two Leading Transplant Organizations
  13. Actinium Pharmaceuticals to Present at Source Capital Group’s 2017 Disruptive Growth & Healthcare Conference
  14. Actinium Pharmaceuticals’ Company Presentation at BIO CEO & Investor Conference to Provide Highlights of Recently Announced Actimab-M Trial in Multiple Myeloma 
  15. Actinium Pharmaceuticals (ATNM) has Considerable Potential in 2017
  16. Actinium Pharmaceuticals to Present at BIO CEO & Investor Conference
  17. Actinium Pharmaceuticals Is Better Than Celator
  18. Actinium Pharmaceuticals Announces Pipeline Expansion with Initiation of Clinical Trial of Actimab-M in Multiple Myeloma
  19. Key Catalyst That Could Send Biotechs Soaring in 2017: Today's Reports on MYOS RENS Technology and Actinium Pharmaceuticals
  20. Actinium’s Chief Medical Officer, Dr. Mark Berger, to Present Talk Titled, Iomab-B: Radiolabeled CD45 at the 3rd Annual Expert Forum on Acute Leukemias and Myeloproliferative Neoplasms